argenx NV ADR (ARGX)vsYum! Brands Inc (YUM)
ARGX
argenx NV ADR
$782.17
-0.65%
HEALTHCARE · Cap: $49.20B
YUM
Yum! Brands Inc
$151.95
-3.37%
CONSUMER CYCLICAL · Cap: $43.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Yum! Brands Inc generates 79% more annual revenue ($8.49B vs $4.74B). ARGX leads profitability with a 31.4% profit margin vs 20.5%. ARGX appears more attractively valued with a PEG of 1.30. ARGX earns a higher WallStSmart Score of 75/100 (B).
ARGX
Strong Buy75
out of 100
Grade: B
YUM
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.4%
Fair Value
$2344.11
Current Price
$782.17
$1561.94 discount
Margin of Safety
-76.3%
Fair Value
$90.20
Current Price
$151.95
$61.75 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Every $100 of equity generates 20 in profit
Strong operational efficiency at 31.0%
Earnings expanding 72.2% YoY
Keeps 21 of every $100 in revenue as profit
15.2% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.4x book value
Expensive relative to growth rate
Moderate valuation
ROE of 0.0% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : YUM
The strongest argument for YUM centers on Operating Margin, EPS Growth, Profit Margin. Profitability is solid with margins at 20.5% and operating margin at 31.0%. Revenue growth of 15.2% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : YUM
The primary concerns for YUM are PEG Ratio, P/E Ratio, Return on Equity.
Key Dynamics to Monitor
YUM carries more volatility with a beta of 0.60 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (75/100 vs 65/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Yum! Brands Inc
CONSUMER CYCLICAL · RESTAURANTS · USA
Yum! Brands, Inc. is an American fast food corporation listed on the Fortune 1000. Yum! operates the brands KFC, Pizza Hut, Taco Bell, The Habit Burger Grill, and WingStreet worldwide, except in China, where the brands are operated by a separate company, Yum China.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?